Cutting edge: Anti–TIM-3 treatment exacerbates pulmonary inflammation and fibrosis in mice

Journal of Immunology

Volumn 199, Issue 11, 2017, Pages 3733-3737

  Isshiki, Takuma ^b   Akiba, Hisaya ^a   Nakayama, Masafumi ^c   Harada, Norihiro ^a   Okumura, Ko ^a   Homma, Sakae ^b   Miyake, Sachiko ^a  

^a JUNTENDO UNIVERSITY   (Japan)

^b TOHO UNIVERSITY OMORI MEDICAL CENTER   (Japan)

^c TOHOKU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BLEOMYCIN; IMMUNOGLOBULIN G; INTERLEUKIN 6; MONOCLONAL ANTIBODY; SCATTER FACTOR; SMAD7 PROTEIN; T CELL IMMUNOGLOBULIN AND MUCIN DOMAIN 3 MONOCLONAL ANTIBODY; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; COLLAGEN; HAVCR2 PROTEIN, MOUSE; HEPATITIS A VIRUS CELLULAR RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; B LYMPHOCYTE; BLEOMYCIN INDUCED LUNG FIBROSIS; BLEOMYCIN INDUCED LUNG INFLAMMATION; BLEOMYCIN INDUCED LUNG INJURY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COUNT; COLLAGEN DEPOSITION; COLLAGEN METABOLISM; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG INDUCED DISEASE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUNG ALVEOLUS EPITHELIUM CELL; LUNG ALVEOLUS MACROPHAGE; LUNG INJURY; LUNG LAVAGE; MALE; MOUSE; MYOFIBROBLAST; NATURAL KILLER CELL; NONHUMAN; PERIBRONCHIOLAR FIBROSIS; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; ANIMAL; C57BL MOUSE; CELL CULTURE; CHEMICALLY INDUCED; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; LUNG; LUNG FIBROSIS; METABOLISM; PATHOLOGY; PNEUMONIA; PROCEDURES;

ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; BLEOMYCIN; CELLS, CULTURED; COLLAGEN; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; HUMANS; IMMUNOTHERAPY; LUNG; MACROPHAGES, ALVEOLAR; MALE; MICE; MICE, INBRED C57BL; MYOFIBROBLASTS; PNEUMONIA; PULMONARY FIBROSIS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 85034739461     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1700059     Document Type: Article

References (31)

1. Sharma, P., and J. P. Allison. 2015. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161: 205–214.
2. Mahoney, K. M., P. D. Rennert, and G. J. Freeman. 2015. Combination cancer immunotherapy and new immunomodulatory targets. Nat. Rev. Drug Discov. 14: 561–584.
3. Topalian, S. L., C. G. Drake, and D. M. Pardoll. 2015. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27: 450–461.
4. Walunas, T. L., D. J. Lenschow, C. Y. Bakker, P. S. Linsley, G. J. Freeman, J. M. Green, C. B. Thompson, and J. A. Bluestone. 1994. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1: 405–413.
5. Krummel, M. F., and J. P. Allison. 1995. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182: 459–465.
6. Grosso, J. F., and M. N. Jure-Kunkel. 2013. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun. 13: 5
7. Okazaki, T., S. Chikuma, Y. Iwai, S. Fagarasan, and T. Honjo. 2013. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat. Immunol. 14: 1212–1218.
8. Iwai, Y., M. Ishida, Y. Tanaka, T. Okazaki, T. Honjo, and N. Minato. 2002. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. USA 99: 12293–12297.
9. Anderson, A. C. 2014. Tim-3: an emerging target in the cancer immunotherapy landscape. Cancer Immunol. Res. 2: 393–398.
10. Ngiow, S. F., M. W. Teng, and M. J. Smyth. 2011. Prospects for TIM3-targeted antitumor immunotherapy. Cancer Res. 71: 6567–6571.
11. Monney, L., C. A. Sabatos, J. L. Gaglia, A. Ryu, H. Waldner, T. Chernova, S. Manning, E. A. Greenfield, A. J. Coyle, R. A. Sobel, et al. 2002. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 415: 536–541.
12. Sakuishi, K., L. Apetoh, J. M. Sullivan, B. R. Blazar, V. K. Kuchroo, and A. C. Anderson. 2010. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. [Published erratum appears in 2011 J. Exp. Med. 208: 1331.] J. Exp. Med. 207: 2187–2194.
13. Ngiow, S. F., B. von Scheidt, H. Akiba, H. Yagita, M. W. Teng, and M. J. Smyth. 2011. Anti-TIM3 antibody promotes T cell IFN-g-mediated antitumor immunity and suppresses established tumors. Cancer Res. 71: 3540–3551.
14. Zhou, Q., M. E. Munger, R. G. Veenstra, B. J. Weigel, M. Hirashima, D. H. Munn, W. J. Murphy, M. Azuma, A. C. Anderson, V. K. Kuchroo, and B. R. Blazar. 2011. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood 117: 4501–4510.
15. Zhu, C., A. C. Anderson, A. Schubart, H. Xiong, J. Imitola, S. J. Khoury, X. X. Zheng, T. B. Strom, and V. K. Kuchroo. 2005. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat. Immunol. 6: 1245–1252.
16. Nakayama, M., H. Akiba, K. Takeda, Y. Kojima, M. Hashiguchi, M. Azuma, H. Yagita, and K. Okumura. 2009. Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation. Blood 113: 3821–3830.
17. DeKruyff, R. H., X. Bu, A. Ballesteros, C. Santiago, Y. L. Chim, H. H. Lee, P. Karisola, M. Pichavant, G. G. Kaplan, D. T. Umetsu, et al. 2010. T cell/ transmembrane, Ig, and mucin-3 allelic variants differentially recognize phosphatidylserine and mediate phagocytosis of apoptotic cells. J. Immunol. 184: 1918–1930.
18. Huang, Y. H., C. Zhu, Y. Kondo, A. C. Anderson, A. Gandhi, A. Russell, S. K. Dougan, B. S. Petersen, E. Melum, T. Pertel, et al. 2015. CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature 517: 386–390.
19. Chiba, S., M. Baghdadi, H. Akiba, H. Yoshiyama, I. Kinoshita, H. Dosaka-Akita, Y. Fujioka, Y. Ohba, J. V. Gorman, J. D. Colgan, et al. 2012. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat. Immunol. 13: 832–842.
20. Callahan, M. K., M. A. Postow, and J. D. Wolchok. 2016. Targeting T cell co-receptors for cancer therapy. Immunity 44: 1069–1078.
21. Naidoo, J., D. B. Page, B. T. Li, L. C. Connell, K. Schindler, M. E. Lacouture, M. A. Postow, and J. D. Wolchok. 2015. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann. Oncol. 26: 2375–2391
22. Ashcroft, T., J. M. Simpson, and V. Timbrell. 1988. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J. Clin. Pathol. 41: 467–470.
23. Makino, F., J. Ito, Y. Abe, N. Harada, F. Kamachi, H. Yagita, K. Takahashi, K. Okumura, and H. Akiba. 2012. Blockade of CD70-CD27 interaction inhibits induction of allergic lung inflammation in mice. Am. J. Respir. Cell Mol. Biol. 47: 298–305.
24. Moeller, A., K. Ask, D. Warburton, J. Gauldie, and M. Kolb. 2008. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int. J. Biochem. Cell Biol. 40: 362–382.
25. Shimabukuro, D. W., T. Sawa, and M. A. Gropper. 2003. Injury and repair in lung and airways. Crit. Care Med. 31(8, Suppl.): S524–S531.
26. Watanabe, M., M. Ebina, F. M. Orson, A. Nakamura, K. Kubota, D. Koinuma, K. Akiyama, M. Maemondo, S. Okouchi, M. Tahara, et al. 2005. Hepatocyte growth factor gene transfer to alveolar septa for effective suppression of lung fibrosis. Mol. Ther. 12: 58–67.
27. Shukla, M. N., J. L. Rose, R. Ray, K. L. Lathrop, A. Ray, and P. Ray. 2009. Hepatocyte growth factor inhibits epithelial to myofibroblast transition in lung cells via Smad7. Am. J. Respir. Cell Mol. Biol. 40: 643–653.
28. Misharin, A. V., L. Morales-Nebreda, G. M. Mutlu, G. R. Budinger, and H. Perlman. 2013. Flow cytometric analysis of macrophages and dendritic cell subsets in the mouse lung. Am. J. Respir. Cell Mol. Biol. 49: 503–510.
29. Lee, Y. J., C. Moon, S. H. Lee, H. J. Park, J. Y. Seoh, M. S. Cho, and J. L. Kang. 2012. Apoptotic cell instillation after bleomycin attenuates lung injury through hepatocyte growth factor induction. Eur. Respir. J. 40: 424–435.
30. Grabiec, A. M., and T. Hussell. 2016. The role of airway macrophages in apoptotic cell clearance following acute and chronic lung inflammation. Semin. Immunopathol. 38: 409–423.
31. Chabtini, L., B. Mfarrej, M. Mounayar, B. Zhu, I. Batal, P. J. Dakle, B. D. Smith, O. Boenisch, N. Najafian, H. Akiba, et al. 2013. TIM-3 regulates innate immune cells to induce fetomaternal tolerance. J. Immunol. 190: 88–96.